Dr. Chughtai discusses new pilot study on Rezum treatment for BPH

Video

“We found that the adverse event rates have dropped dramatically, to about a third of what it was reported in the pivotal trial, but at the same time still had the same net benefits in terms of efficacy when it comes to Q max, symptomatic improvement, as well as PVR," said Bilal Chughtai, MD.

In this video, Bilal Chughtai, MD, an associate professor of Urology at Weill Cornell Medical College, discusses the background and findings of his recent paper, "Pilot study of ‘less is more’ Rezum for treatment of BPH."

Related Videos
Jenny Guo, MD, answers a question during a Zoom video interview
Dr. Dean S. Elterman in an interview with Urology Times
Illustration of enlarged prostate | Image Credit: © Judith - stock.adobe.com
Dr. Dean Elterman in an interview with Urology Times
Dr. Nicholas S. Dean in an interview with Urology Times
Jasmine Lin, MD, answers a question during a Zoom video interview
© 2023 MJH Life Sciences

All rights reserved.